Pathology Unit, F. Addarii Institute of Oncology and Transplantation Pathology, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.
Dig Liver Dis. 2013 Jun;45(6):505-9. doi: 10.1016/j.dld.2012.11.015. Epub 2013 Jan 12.
While the role of serum HCV RNA quantitation in hepatitis C virus recurrence after liver transplantation is well established, the meaning of HCV RNA tissue quantitation is largely unclear, and no correlations with recipient outcome have been investigated yet.
To assess the predictive value, and a possible prognostic role, of tissue and serum HCV RNA in first post-transplant biopsies.
We retrospectively reviewed the first post-transplant biopsies of 83 recipients. Tissue and serum HCV RNA was quantitated by RT-PCR, and compared with serum, clinical and histological data.
HCV RNA quantitation allowed us to categorise recipients into three different risk groups: (1) tissue HCV RNA ≤ 1.5 IU/ng with any serum HCV RNA; (2) tissue HCV RNA>1.5 IU/ng and serum HCV RNA < 40 × 10(6)copies/mL; (3) tissue HCV RNA>1.5 IU/ng and serum HCV RNA ≥ 40 × 10(6)copies/mL. Hepatitis C virus recurrence rates in the three groups were 68%, 91% and 100% (P=0.004); hepatitis C virus-related mortality was 0%, 14% and 45% respectively (P<0.001).
This preliminary study on serum and tissue HCV RNA quantitation allows recipient "stratification" in prognostic groups, which could be applicable in the future for timely antiviral treatment and/or immunosuppression modulation.
虽然血清 HCV RNA 定量在丙型肝炎病毒（HCV）肝移植后复发中的作用已得到充分证实，但 HCV RNA 组织定量的意义在很大程度上尚不清楚，且尚未研究其与受者结局的关系。
评估组织和血清 HCV RNA 在移植后首次活检中的预测价值及其可能的预后作用。
我们回顾性分析了 83 例受者的移植后首次活检。采用 RT-PCR 定量检测组织和血清 HCV RNA，并与血清、临床和组织学数据进行比较。
HCV RNA 定量可将受者分为 3 个不同的风险组：（1）组织 HCV RNA≤1.5 IU/ng 且血清 HCV RNA 任何水平；（2）组织 HCV RNA>1.5 IU/ng 且血清 HCV RNA<40×10^6 拷贝/mL；（3）组织 HCV RNA>1.5 IU/ng 且血清 HCV RNA≥40×10^6 拷贝/mL。3 组 HCV 复发率分别为 68%、91%和 100%（P=0.004）；HCV 相关死亡率分别为 0%、14%和 45%（P<0.001）。
本研究初步探讨了血清和组织 HCV RNA 定量，可将受者分为不同的预后组，未来可能适用于及时进行抗病毒治疗和/或免疫抑制调节。
